MVA-1b

MVA 1b: A Cancer Research UK Phase Ib trial to determine the safety, tolerability and immunogenicity of extended schedule vaccination with MVA-EBNA1/LMP2 in patients with Epstein Barr Virus positive nasopharyngeal carcinoma

Chief Investigator:	Dr Neil Steven
Sponsor:	Cancer Research UK
Funder:	CR UK Clinical Trials Unit
Disease Site:	Mixed Primary Cancer
Trial Type:	Clinical Trial of an Investigational Medicinal Product
Status:	Complete
EudraCT Number:	2012-002625-30
ClinicalTrials.Gov ID:	NCT01800071
Open to New Sites?	No
Recruitment Start Date:	18-Mar-2014
Recruitment End Date:	09-Mar-2015
CRCTU Trial Management Team:	EDD
Trial Email Address:	can-crctu-edd@adf.bham.ac.uk

Trial Summary

This trial is looking at a vaccine that may help the immune system to recognise and kill nasopharyngeal cancer cells containing a virus called Epstein Barr (EBV). The trial is supported by Cancer Research UK.

EBV is a common virus that many people carry without noticing any effects. But the virus is sometimes found in cancer cells and is often found in nasopharyngeal cancer cells.

Vaccines can help the immune system to recognise and act against a virus. Researchers hope a vaccine that gets the body’s immune system to recognise and attack EBV might kill cancer cells containing the virus.

Doctors usually treat nasopharyngeal cancer with radiotherapy or a combination of radiotherapy and chemotherapy (chemoradiation). The people taking part in this trial have already had treatment and their cancer has responded well. Or they still have some cancer remaining, but no other treatment is appropriate or needed at this time. The vaccine, which is called MVA-EBNA1/LMP2, may make it less likely for their cancer to come back or get worse.

In an earlier trial, researchers found the highest safe dose of the vaccine you can have. In this trial, they want to learn more about:

• How your immune system responds to the vaccine
• Side effects
• The effect an extra dose of the vaccine has on your immune system

Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible.

Trial Summary

• View Trial Summary Document

Please Note:
Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional.
Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.